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PSTATE-OF-THE-ART PAPER AND COMMENTARY
Intravascular Ultrasound for the Evaluation
of Therapies Targeting Coronary Atherosclerosis
Dirk Böse, MD,* Clemens von Birgelen, MD, PHD,† Raimund Erbel, MD*
Essen, Germany; and Enschede, the Netherlands
Many cardiovascular events are clinical manifestations of underlying atherosclerotic disease. The progression of
atherosclerosis, traditionally measured by angiography, is predictive of future clinical events and is a valid surro-
gate marker of cardiovascular (CV) disease. There is growing interest in using novel surrogate end points in clini-
cal trials to expedite the development of new CV therapies. Innovative imaging technologies, such as intravascu-
lar ultrasound (IVUS), may carry advantages for the evaluation of coronary atherosclerotic burden and disease
progression. Unlike angiography, which displays only the opacified luminal “silhouette,” IVUS provides transmural
imaging of the entire arterial wall and permits both detection of early-stage atherosclerosis and accurate cross-
sectional and even 3-dimensional quantification of plaques. Intravascular ultrasound is now used to guide thera-
peutic interventions and for diagnostic purposes, primarily for the evaluation of ambiguous lesions and left main
coronary artery disease. In addition, clinical studies are using IVUS serially to measure plaque progression, which
appears to be related to future CV events. Although the probative force of clinical end point studies still is stron-
ger, IVUS is catching up. Currently, several trials of CV therapies use IVUS-determined plaque progression as the
end point. The rationale for using IVUS-based surrogate end points in clinical trials is discussed in the present
review. Key advantages of using IVUS-based surrogate end points versus clinical outcome include smaller patient
numbers and substantially shorter trial durations; this reduces costs and may expedite the development and
testing of new drugs. We expect in the near future a further increase of the use of IVUS-based surrogate end
points in trials that evaluate novel CV therapies targeting on coronary atherosclerosis. (J Am Coll Cardiol 2007;
49:925–32) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.067p
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flthough the use of pharmacotherapy for primary and
econdary prevention of cardiovascular disease (CVD) is
idely accepted, a considerable number of patients still
xperience cardiovascular (CV) events. Consequently, the
evelopment of more effective treatment of CVD remains a
ey objective of CV research. A key stage in the develop-
ent of novel therapies is the demonstration of a significant
linical benefit in terms of a reduction in CV morbidity and
ortality. Clinical end point trials with sufficient statistical
ower to detect differences between an established and a
ovel therapeutic regimen are inevitably large and require a
ong study duration, often necessitating the follow-up of
everal thousand patients (1). This has economic and
ogistical implications, as highlighted in a recent editorial
2), and has encouraged the consideration of alternative trial
esigns and end points for the evaluation of novel CV
herapies.
rom the *Department of Cardiology, University of Duisburg-Essen, Essen, Ger-
any; and the †Department of Cardiology, Medisch Spectrum Twente, Enschede,
he Netherlands.a
Manuscript received February 28, 2006; revised manuscript received August 21,
006, accepted August 26, 2006.A surrogate end point may be defined as a measure of a
athophysiologic process that is characteristic of future
linical outcome or end points. A surrogate end point allows
orrectly inferring the effect of a therapeutic intervention on
n unobserved clinical end point. Using appropriate surro-
ate end points in trials can enable the detection of
tatistically significant differences between therapeutic reg-
mens with substantially smaller sample sizes within a
horter period of time (1). Thus, use of surrogate end points
an potentially expedite drug development, providing ben-
fits for both the medical community and patients. The
bjective of the present review is to present evidence
upporting IVUS assessment of atherosclerotic plaque pro-
ression as a surrogate marker for CV events.
ngiography, Atherosclerotic
rogression, and CV Events
ost coronary events are clinical manifestations of under-
ying atherosclerotic disease. Traditionally, coronary an-
iography has been used for imaging of CVD; it has
emonstrated that atherosclerotic plaque progression, in-
erred by progressive angiographic luminal obstruction, is
ssociated with an increased rate of CV events.
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IVUS for the Evaluation of CV Therapies March 6, 2007:925–32In the Cholesterol-Lowering
Atherosclerosis Study (3), 162
patients with previous coronary
artery bypass graft (CABG) sur-
gery were randomized to lipid-
lowering therapy with colestipol/
niacin or to placebo. Coronary
angiograms were conducted at
baseline and after 2 years. Ath-
erosclerotic disease was assessed
qualitatively by a consensus panel
evaluation (global change score)
and quantitatively by measuring
the mean change in percentage
diameter stenosis (%DS) and the
minimum lumen diameter. Ath-
erosclerotic progression at 2 years
by global change score, %DS, or
minimum lumen diameter was
associated with a significantly in-
creased rate of coronary events
(p  0.05). In mild to moderate
lesions (50%DS), every in-
rease of 10%DS or 0.3 mm decrease in minimum lumen
iameter was associated with a relative risk of 2.1 (95% CI
.4 to 3.0; p  0.001) and 1.8 (95% CI 1.4 to 2.4; p 
.001), respectively, for any future coronary event.
In a clinical trial of nicardipine in 335 patients without
revious or planned CABG surgery or angioplasty (4),
therosclerosis was assessed by angiography at baseline and
fter 2 years. Plaque progression, defined as an increase of at
east 15%DS in 1 or more coronary lesions, was observed in
41 patients and was significantly associated with future
oronary events. During the follow-up period, 16 of 19
ardiac deaths occurred in patients with plaque progression,
epresenting a relative risk of 7.3 (95% CI 2.2 to 24.7; p 
.001) versus patients with no evidence of plaque progres-
ion. Patients with disease progression also had an increased
isk of cardiac death or nonfatal infarction (relative risk 2.3,
5% CI 1.3 to 4.2; p  0.009) (4).
Angiographic evidence from trials suggests that stabilization
f atherosclerosis is associated with reduced rates of CV events.
n the High-Density Lipoprotein Atherosclerosis Treatment
tudy, 160 patients with coronary heart disease (CHD) were
andomized to 1 of 4 treatment regimens, including the
ombination of simvastatin and/or niacin, or placebo (5).
oronary angiography was conducted at baseline and after 3
ears; at follow-up, mean percentage stenosis in proximal
rteries had increased by an average of 3.9% in patients
eceiving placebo but had decreased by 0.4% in patients
eceiving simvastatin plus niacin therapy (p  0.001 vs.
lacebo). The frequency of the composite primary end point
death from coronary causes, confirmed myocardial infarction
MI], stroke, and revascularization for worsening ischemia
ymptoms) was 90% lower in patients on simvastatin plus
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CSA  cross-sectional area
CV  cardiovascular
CVD  cardiovascular
disease
%DS  percentage
diameter stenosis
EEM  external elastic
membrane
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
IVUS  intravascular
ultrasound
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarctioniacin than on placebo (3% vs. 24%; p  0.04). cimitations of Coronary Angiography
ver the past 2 decades, a new paradigm for atherogenesis
as emerged. Atherosclerosis primarily affects the arterial
all, with atherosclerotic plaque growth initially accommo-
ated in an outwardly expanding vessel wall (positive
emodeling) (6). Owing to this process, angiographically
etectable stenosis does not occur during the early stages of
laque accumulation when the increasing total vessel occu-
ies the increasing amount of plaque mass (6). Although
ositively remodeled lesions do not restrict blood flow, they
ay be unstable and may contribute to the onset of acute
oronary syndromes (7–9). The increased understanding of
therogenesis has highlighted inherent limitations of coro-
ary angiography as a technique for the assessment of
oronary atherosclerosis (10).
Angiography provides a 2-dimensional view of the arte-
ial lumen, but with no visualization of the vessel wall.
herefore, as a result of positive remodeling, angiography
requently fails to detect the early stages of atherosclerosis
6,11). Furthermore, owing to its reliance on comparing
utative sites of stenosis with an apparently normal (refer-
nce) arterial segment, angiography often fails to detect
iffuse disease in which the entire artery may be impacted by
therosclerotic disease (12). Visual assessment of angio-
rams is subject to significant variation in image interpre-
ation (observer bias) which may lead to a significant
nderestimation of lesion severity, as determined by post-
ortem histologic analysis (12,13).
VUS and the Imaging of Atherosclerotic Disease
wing to the limitations of angiography, a variety of
lternative invasive and noninvasive diagnostic techniques
ave been explored for a more accurate imaging of athero-
clerotic coronary vessels. Intravascular ultrasound, for ex-
mple, is a catheter-based technique that provides high-
esolution cross-sectional images of the coronary vessel in
ivo. In daily clinical practice, IVUS is a widespread method
or the visualization of coronary lumen, vessel wall, and
therosclerotic plaque formation (14). The coronary artery is
ubselectively cannulated by a catheter incorporating a
iniature transducer which emits high-frequency ultra-
ound (usually in the range of 20 to 50 MHz). As the
ransducer is moved through the artery, ultrasonic reflec-
ions are electronically converted to cross-sectional images.
Qualitative and quantitative IVUS analyses are usually
erformed according to the American College of Cardiol-
gy Clinical Expert Consensus Document on Standards for
cquisition, Measurement and Reporting of Intravascular
ltrasound Studies (15). Lumen cross-sectional area (CSA)
s quantified by planimetry of the leading edge of the
lood-intima acoustic interface. The outer vessel border
external elastic membrane [EEM] CSA) is detected as the
nterface between media and adventitia. Atheroma-CSA is
alculated as the difference between EEM-CSA and lumen-
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March 6, 2007:925–32 IVUS for the Evaluation of CV TherapiesSA (Fig. 1). The use of a motorized pull-back device with
defined pull-back speed (0.5 to 1 mm/s) is the established
ethod to image the entire vessel. This permits a volumetric
ssessment of vessel and plaque dimensions after longitudi-
al or 3-dimensional computer-assisted reconstruction (15)
Fig. 2).
Because IVUS is fundamentally different from angiogra-
hy, it is not subject to the same limitations as angiography.
ntravascular ultrasound can identify diffuse disease and
emodeling of the vessel wall, both of which may be
ommon in atherosclerotic progression and may be deter-
Figure 1 IVUS Cross-Sectional Image of an Atherosclerotic Hum
Determination of plaque cross-sectional area using intravascular ultrasound (IVUS)
external elastic membrane (EEM)–cross-sectional area (CSA)  Lumen-CSA  Plaq
Figure 2 IVUS Cross-Sectional Image and Longitudinal Reconst
(Left) Intravascular ultrasound (IVUS) cross-sectional image; (right) longitudinal re
indicates the position of the cross-sectional image and thus the site of plaque rupinants of clinical outcome (11). Furthermore, IVUS is
ormally more sensitive than angiography for the detection
f stenosis (16). For these reasons, there is frequently a
iscrepancy between the extent and severity of CHD as
iagnosed by IVUS versus angiography (17,18).
In addition, IVUS may be helpful in the detection of
laques with a high risk of spontaneous plaque rupture.
ome typical morphologic criteria of these vulnerable
upture-prone plaques can be identified by IVUS (8,9,19).
laque ruptures typically occur in proximal vessel segments,
n eccentric lesions with positive and expansive remodeling,
oronary Artery
Media-CSA.
on of an Atherosclerotic Coronary Artery With a Plaque Rupture
uction. The line
the longitudinal reconstruction.an C
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IVUS for the Evaluation of CV Therapies March 6, 2007:925–32nd even in plaques with large plaque mass (8,9) (Fig. 2). In
ome cases, an echolucent zone, representing a lipid-rich
ore, can be identified within the plaque by IVUS (9).
Although IVUS offers many advantages over angiogra-
hy, its widespread use in clinical practice may be partially
imited by its invasive nature, which carries a certain level of
isk. For this reason, the safety of IVUS has been rigorously
nvestigated, and data from almost 3,500 examinations
ndicate a low overall rate of acute complications (20–22).
he major complications are dissection and vessel closure,
hich may occur in 0.5% of procedures (nearly always in
atients undergoing simultaneous intracoronary interven-
ions) (21,22). Importantly, IVUS does not appear to
ccelerate atherosclerosis in nontransplant nonintervened
oronary arteries (20). Coronary angiography is still re-
arded by many as the principal imaging technique for
uiding coronary interventions. Nevertheless, IVUS is prov-
ng to be a valuable addition, particularly in the identifica-
ion of angiographically silent atherosclerosis and ambigu-
us lesions.
etection of Coronary
laque Composition Based on IVUS
nitially, conventional grayscale IVUS was used to charac-
erize coronary plaque composition qualitatively by the
chogenicity of different plaque structures. Coronary calci-
cation especially can be well detected (15). Nevertheless,
VUS is limited in the detection and quantification of
pecific plaque components, e.g., lipid-rich tissue and ne-
rotic core (15). Recent technical developments, such as
Figure 3 Plaque Progression/Regression Versus CV Events
Higher rate of cardiovascular (CV) events in patients with plaque progression durin
Modified from von Birgelen et al. (27). PCI  percutaneous coronary intervention;ntegrated backscatter and virtual histology, have focused on
urther mathematical analysis of the radiofrequency signal
nderlying the IVUS grayscale image. These techniques
llow identification and quantification of different plaque
omponents, such as lipid, fibrous tissue, calcification, and
ecrotic core. In addition, color-coded visualization of
ifferent plaque components can be performed (23,24). In a
tudy by Fujii et al. (25), IVUS virtual histology-derived
laque composition of positively remodeled vessels showed
ore fibrofatty content than that of negatively remodeled
esions. Future studies will have to evaluate the potential
dditional values of these new imaging techniques and
hether these methods are able to detect changes in plaque
omposition in addition to the changes in plaque volume. In
he future, these techniques may have the potential to assess
he effects of pharmacologic therapies on plaque composi-
ion. In addition, the possibility of identifying and quanti-
ying the lipid-rich plaque components or the necrotic core
ay open a new window in the detection and analysis of
ulnerable plaques.
ssociation Between
oronary Plaque Progression,
s Measured by IVUS, and CV Events
ecause plaque progression, inferred by progressive angio-
raphic luminal obstruction, has been shown to be associ-
ted with an increased risk of CV events (3,4), it can be
xpected that plaque progression, as measured by IVUS,
hould show a similar and perhaps even stronger association.
w-up.
plaque and media.g follo
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March 6, 2007:925–32 IVUS for the Evaluation of CV Therapiesn emerging body of evidence provides support for this
upposition.
In a study of patients that underwent percutaneous
oronary intervention (26), obstructive left main coronary
rtery disease, detectable by IVUS but angiographically
ilent, was an independent predictor of future cardiac
vents. The IVUS imaging was conducted during percuta-
eous coronary intervention in 107 patients with normal or
ild left main coronary artery disease by both visual
20%DS) and quantitative angiography (mean 4.8%DS).
he IVUS mean area stenosis was 30.2%. Major adverse
ardiac events in 102 patients followed for a median of 29
onths were death (n  6), MI (n  4), repeat percuta-
eous coronary intervention (n 13), and CABG (n 16).
y univariate analysis, these events were significantly asso-
iated with IVUS minimum and mean lumen area, angio-
raphic minimum lumen diameter, female gender, and
iabetes. For every 5 mm2 increase in IVUS minimum and
ean lumen area, the hazard ratio (HR) was 0.59 (p 
.01) and 0.62 (p  0.01), respectively. For every 1 mm
ncrease in angiographic minimum lumen diameter, the HR
as 0.59 (p  0.04). By multivariate analysis, only mini-
um lumen area by IVUS (HR 0.59 for every 5 mm2
ncrease; p  0.015) and diabetes (HR 2.69; p  0.014)
ere significant independent predictors of cardiac events.
A recent retrospective analysis of serial IVUS examina-
ions of patients with established CVD published by von
irgelen et al. (27) demonstrated that plaque progression as
easured by IVUS was associated with a significantly
ncreased risk of clinical events as predicted by established
isk-scoring systems. The IVUS examination of the left
ain coronary artery was conducted in 56 patients during an
nitial coronary angiography and in a repeat procedure after
8 months. Because no validated risk score for secondary
revention was available, the risk of CV events was esti-
ated using 3 established algorithms for determining CVD
isk in primary prevention: Prospective Cardiovascular
ünster, European Systematic Coronary Risk Evaluation,
nd Framingham risk score). By all 3 algorithms, patients at
reatest risk of CV events exhibited significantly greater
laque progression by IVUS than patients at lowest risk
p  0.01 and p  0.05 for absolute and percentage
ncreases in atheroma CSA, respectively). Furthermore, the
stimated risk of clinical events by all three algorithms
xhibited a positive linear correlation with percentage in-
reases in atheroma CSA (r  0.41 to r  0.60; p  0.002
o p  0.0001). During the follow-up period, actual adverse
V events occurred in 18 patients, in whom the annual
laque progression was significantly greater than in the
emaining asymptomatic patients (p  0.001) (Fig. 3). The
forementioned data were obtained from a relatively small
etrospective analysis and may be considered only
hypothesis-generating.” Nevertheless, various recent pro-
pective trials also provided evidence that supports such a
ypothesis, as discussed in the following section.se of IVUS-Measured Changes in
theroma Dimensions as a Surrogate End Point
n accordance with the hypothesis that plaque progression
etected by IVUS is a valid predictive marker for CV events,
everal clinical trials of CV drugs have used IVUS-measured
hanges in atheroma dimensions as surrogate end points
28–32).
The CAMELOT (Comparison of Amlodipine and
nalapril to Limit Occurrences of Thrombosis) and
ORMALISE (Norvasc for Regression of Manifest
therosclerotic Lesions by Intravascular Sonographic
valuation) studies (28) showed that antihypertensive ther-
py with amlodipine reduced IVUS-detected coronary
laque progression and CV events. In the CAMELOT
tudy, 1,991 patients with angiographically documented
HD (20%DS) and normal blood pressure were ran-
omized to receive either 10 mg amlodipine, 20 mg
nalapril, or placebo daily. In a subgroup of 274 patients
NORMALISE), IVUS was conducted at baseline and at
tudy completion. After 24 months of therapy, the incidence
f CV events was significantly lower in amlodipine-treated
atients versus placebo (16.6% vs. 23.1%, HR 0.69, 95% CI
.54 to 0.88; p  0.003) but not in the enalapril-treated
Figure 4 Cholesterol Levels Versus
Plaque Progression Regression
(Top) Positive relation between plaque progression, defined as change in
plaque plus media cross-sectional area/year (P&M CSA/year), versus LDL-C
levels. (Bottom) Negative relation between plaque progression (P&M CSA/
year) versus HDL-C levels. Modified from von Birgelen et al. (33). CSA  cross-
sectional area; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-
density lipoprotein cholesterol; P&M  plaque and media.
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IVUS for the Evaluation of CV Therapies March 6, 2007:925–32roup (20.3%, HR 0.85, 95% CI 0.67 to 1.07; p  0.16).
irroring these differences in CV event incidence, there
as no significant change from baseline in mean percent-
ge IVUS-measured atheroma volume in the amlodipine
roup (p  0.31), a trend toward an increase in the
nalapril group (p  0.08), and a significant increase in
he placebo group (p  0.001).
The linear relation between cholesterol levels and coro-
ary plaque progression as assessed with serial IVUS mea-
urements was first shown in an observational study by von
irgelen et al. (33). Nonstenotic left main coronary arteries
ere examined by IVUS and after 18.3  9.4 months. In
his retrospective analysis, a positive linear relation between
ow-density lipoprotein cholesterol (LDL-C) and plaque
rogression was found (r  0.41; p  0.0001) (Fig. 4). An
DL-C cut-off value of 75 mg/dl was found at which there
as no increase in plaque-CSA (Fig. 5). An inverse rela-
ionship between high-density lipoprotein cholesterol
HDL-C) levels and the annual changes in plaque size was
lso indicated (r  0.32; p  0.01).
Later on, these results were supported by the volumetric
VUS data of the prospective REVERSAL (Reversal of
therosclerosis With Aggressive Lipid Lowering) trial. In
hat study, IVUS examination demonstrated significantly
ore reduction of plaque progression in patients with
ntense lowering of LDL-C versus moderate lowering of
DL-C (29). In the REVERSAL trial, 654 patients with
ngiographically established CHD (20%DS in at least 1
esion) and elevated LDL-C (mean 150.2 mg/dl) were
andomized to receive 80 mg/day atorvastatin or 40 mg/day
ravastatin. The IVUS was conducted at baseline and after
8 months of therapy. With regard to the primary end point
f percentage change in atheroma volume, disease progres-
Figure 5 LDL-C Versus Coronary Plaque Progression/Regressio
(Left) First demonstration of the positive correlation between coronary plaque prog
fied from von Birgelen et al. (33). (Right) Confirmation of the relation between LDL
als. Modified from Nissen SE et al. (36). LDL-C  low-density lipoprotein cholesterion was significantly lower in the atorvastatin group than in
he pravastatin group (p  0.02). Atheroma volume in-
reased from baseline by a mean of 2.4% (95% CI 0.2% to
.7%; p  0.001) in the pravastatin group compared with
mean decrease of 0.4% in the atorvastatin group (95%
I 2.4% to 1.5%; p  0.98). Baseline LDL-C levels
ere reduced to a mean of 110 mg/dl and 79 mg/dl in the
ravastatin and atorvastatin groups, respectively (p 
.001). This LDL-C value of patients on atorvastatin who
ad virtually no change in plaque dimensions is almost
dentical to the threshold at which no progression oc-
urred in the observational study by von Birgelen et al.
33) (Fig. 5).
The REVERSAL study used the same treatment regi-
en as the PROVE IT (Pravastatin or Atorvastatin Eval-
ation and Infection Therapy) study, which reported a
ignificantly greater reduction in CV events in patients with
cute coronary syndromes after treatment for 2 years with
0 mg/day atorvastatin compared with 40 mg/day pravasta-
in (34). Although the REVERSAL and PROVE IT
tudies were distinct studies, when considered together their
esults provide further evidence that atherosclerotic progres-
ion measured by IVUS is predictive of an increased risk of
V events.
There are other studies that indicate that lipid-lowering
herapy may not only slow down plaque progression but may
ven induce plaque regression. Okazaki et al. (30) analyzed
he impact of aggressive lipid-lowering therapy on coronary
laque volume in patients with acute coronary syndrome
ith serial IVUS. In the ESTABLISH study, the patients
ere randomized to a lipid-lowering therapy (20 mg/day
torvastatin) or no lipid-lowering therapy (control group).
fter therapy with atorvastatin for 6 months, there was a
n by intravascular ultrasound and LDL-C levels in an observational study. Modi-
coronary plaque progression by data derived from various large randomized tri-
M  plaque and media.n
ressio
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March 6, 2007:925–32 IVUS for the Evaluation of CV Therapiesignificant plaque volume reduction by IVUS (13.1% 
2.8%) and a significant positive relation between the
DL-C reduction and the reduction in plaque volume (r 
.612; p  0.0001) (30).
The relationship between LDL-C lowering and the IVUS-
easured regression of atherosclerotic plaque volume could
lso be demonstrated in the LACMART (Low-Density Li-
oprotein Apheresis Coronary Morphology and Reserve Trial)
35), which assessed the effect of LDL-C lowering by
edication alone or in combination with LDL-apheresis on
oronary atherosclerosis in patients with familial hypercho-
esterolemia. The patients treated with LDL-apheresis
howed a significant lowering of total cholesterol (28.4%)
nd LDL-C (34.3%), whereas the medication group
howed no changes in cholesterol levels (35). At 12 months
ollow-up, IVUS measurements showed a decrease in
laque area in patients treated by aggressive lipid-lowering
herapy (LDL-apheresis group) versus an increase in plaque
rea in the medication group (p  0.008).
Those results were emphasized by ASTEROID (A Study
o Evaluate the Effect of Rouvastatin On Intravascular
ltrasound-Derived Coronary Atheroma Burden), which
valuated the effect of maximally intensive statin therapy
ith 40 mg/day rosuvastatin on coronary plaque progression
r regression as assessed with serial IVUS examination (36).
total of 507 patients were included in this study, and 349
atients had a follow-up examination after 24 months.
nder therapy, the mean baseline LDL-C levels were
educed from 130.4  34.3 mg/dl to 60.7  20.1 mg/dl
mean reduction of 53.2%), and the HDL-C levels showed
n increase from 43.1  11.1 mg/dl to 49.2  12.6 mg/dl
mean increase of 14.6%). The IVUS measurements dem-
nstrated a reduction of total plaque volume by 6.8%
14.7  25.7 mm3) after lipid-lowering therapy of 24
onths (p  0.001 compared with baseline) (Fig. 5).
dvantages of Using IVUS-Based
urrogate End Points for Evaluation
f Novel Therapies Targeting Atherosclerosis
he assessment of morbidity and mortality as end points of
arge clinical trials is associated with a substantial burden in
erms of resources (1). The recent development of effective
harmacotherapies that further reduce the incidence of CV
vents aggravates this problem, because novel agents must
ow prove to be superior to those therapies rather than to
lacebo. Thus, demonstrating greater efficacy for a novel
herapy versus an existing therapy in a clinical end point trial
as become more challenging and may require further
ncreases in study sample size, duration, or both.
In contrast, surrogate end points allow trials of novel
VD therapies to be conducted within a shorter time frame
nd with fewer participants. Consequently, the use of
urrogate end points as an alternative to clinical end points
ay expedite the process of drug development and testing.
s a consequence, this approach reduces costs, which iseneficial for both patients and the medical community.
ven as a complement to clinical end points, the use of
urrogate markers enables pharmaceutical companies and
egulatory bodies to evaluate the potential benefits of novel
rugs until clinical end point data become available.
The emerging body of evidence validating IVUS-
etected progression of coronary atherosclerosis as a surro-
ate marker of future CV events suggests its use in clinical
rials (37). Indeed, IVUS may be a particularly suitable
echnique for this purpose, given its ability to detect
arly-stage disease (i.e., angiographically silent atheroscle-
osis) which can be a precursor of future coronary events.
onclusions
s the global burden of CVD increases in the aging
opulation, the need for surrogate end points to maximize
fficacy in the evaluation of new CVD therapies is likely to
row. Most coronary events are a consequence of underlying
therosclerosis, so that measuring the progression of this
athophysiologic state has attracted much attention for
redicting clinical outcomes. Currently, the inherent limi-
ations of angiography in providing a clinically relevant
icture of arterial disease are clearly recognized. Intravascu-
ar ultrasound, on the other hand, provides a different means
f imaging coronary arteries and is not subject to the same
imitations of coronary angiography. There is growing
vidence from clinical studies that IVUS-measured in-
reases in coronary plaque dimensions predict future CV
vents, which supports its validity as a surrogate end point in
rials that assess novel pharmacologic therapies.
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